Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company is headquartered in Cambridge, Massachusetts and currently employs 197 full-time employees. The company went IPO on 2020-07-16. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. The company is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.
Follow-Up Questions
Qui est le CEO de Relay Therapeutics Inc ?
Dr. Sanjiv Patel est le President de Relay Therapeutics Inc, il a rejoint l'entreprise depuis 2017.
Quelle est la performance du prix de l'action RLAY ?
Le prix actuel de RLAY est de $6.34, il a decreased de 2.23% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Relay Therapeutics Inc ?
Relay Therapeutics Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de Relay Therapeutics Inc ?
La capitalisation boursière actuelle de Relay Therapeutics Inc est de $1.0B
Est-ce que Relay Therapeutics Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 11 analystes ont établi des notations d'analystes pour Relay Therapeutics Inc, y compris 7 achat fort, 8 achat, 3 maintien, 0 vente et 7 vente forte
